retatrutide safety clinical trial liver Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Triple hormone receptor agonist retatrutide – Retatrutide 20mg — Research Peptide

The simultaneous activation of GLP-1, GIP, and glucagon receptors appears to create synergistic interactions that enhance both weight loss and metabolic improvements

Research shows it may help protect the stomach and intestines from damage caused by common painkillers, and it helps keep the inner lining of these organs healthy

The impact of IGF-1 LR3 on human-derived tissue models and preclinical studies reveals significant anabolic and regenerative effects, especially in muscle and connective tissue systems

Pregnancy warning Weight loss medications are not appropriate during pregnancy or while trying to conceive

Cell 165(7):16321643

Trojacanec S, Bobos S, Pajic M